Utilización de células mesenquimales estromales adiposas para el tratamiento coadyuvante de la gingivoestomatitis crónica felina en un caso clínico refractario

Zusammenfassung

We present a 4-year-old, 3.7 kg of weight, ovariohysterectomized, common European female cat diagnosed with feline chronic gingivostomatitis (FCGS) in 2020, which proved to be refractory to conventional medical-surgical treatments. Cell therapy based on autologous adipose-derived mesenchymal stromal cells (AT-MSC) was started as an adjuvant treatment to interferon-omega, cyclosporine, and a hypoallergenic diet. To obtain these cells, a surgical extraction of subcutaneous adipose tissue was performed. This was processed, and the AT-MSCs were isolated, cultured, and expanded (up to the 4th subculture). Once this process was completed, the cells were intravenously and intralesionally administered to the patient. Her evolution was monitored using the SDAI (Stomatitis Disease Activity Index) scoring system for 16 months. One month after the administration of AT-MSC, there was a very significant decrease in the SDAI score, with a decrease in oral mucosal inflammation and an increase in appetite, activity level, and grooming. A second cell dose was administered one year after the first. Currently, the cat continues under veterinary supervision and remains stable. The use of AT-MSC could represent a therapeutic alternative in refractory cases of FCGS. Its intravenous and intraoral administration has proved to be safe and effective as an adjuvant treatment to conventional treatments in the clinical case exposed, obtaining a very favourable result and a substantial improvement in her quality of life.